CAR T trial for relapsed myeloma targeting GPRC5D
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and you have relapsed or refractory multiple myeloma or plasma cell leukemia.
- You have already tried at least 3 different treatment “lines,” including chemotherapy that uses proteasome inhibitors and at least some immunomodulatory (IMiD) drugs.
- Your tumor tissue (often bone marrow) must test positive for GPRC5D on cell surfaces using a lab test (IHC or flow cytometry).
- Your disease must be measurable (for example, specific abnormal blood/urine protein levels or at least 10% plasma cells in bone marrow tests).
- You must be healthy enough for treatment: good blood counts, liver/kidney function, blood clotting, oxygen level, and heart strength (ejection fraction at least 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.